Table 2

Proliferation. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on proliferation of HUVEC, HCAEC, and HCMSMC in comparison to untreated controls at day six after seeding, C = control, (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***; paired Student's t-test)

Proliferation (%)

HUVEC

HCAEC

HCMSMC

C

100 ± 0

100 ± 0

100 ± 0

0,0002 μg/ml Abciximab

96,41 ± 6,16

88,5 ± 7,2

100,18 ± 17,10

0,002 μg/ml Abciximab

93,77 ± 3,88

87,17 ± 9,02

91,86 ± 15,64

0,02 μg/ml Abciximab

90,19 ± 1,77

88,35 ± 3,04

90,85 ± 11,33

0,2 μg/ml Abciximab

90,37 ± 7,38

85,09 ± 8,27

86,90 ± 8,43

2 μg/ml Abciximab

83,47 ± 2,51

91,87 ± 3,25

85,79 ± 8,56

20 μg/ ml Abciximab

79,34 ± 9,16

87,70 ± 6,01

81,09 ± 7,59

Voisard et al. BMC Cardiovascular Disorders 2006 6:14   doi:10.1186/1471-2261-6-14